Skip To Main Content
Bartosz Chmielowski on Muck Rack

Bartosz Chmielowski

As seen in: Nature, Wiley Online Library, The BMJ, The Lancet, Cell Press, Healio, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bartosz

Contact Bartosz, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial - Nature Cancer

|
By Kari Kendra, Katie Campbell Verified, Alexandra Ikeguchi, Andrew S. Brohl, Bartosz Chmielowski, Egmidio Medina, Jia Chen, Sapna P. Patel, Michael Wu
| Nature Verified
Abstract The phase 2 SWOG S1512 trial (NCT02775851) was designed to evaluate the response to pembrolizumab (anti-PD-1) in individuals with desmoplastic melanoma. Here we report the results of cohort A of the trial, evaluating the pathological complete response (pCR) rate of neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma. Secondary endpoints included clinical response rate, overall survival and toxicities.
Open in Who Shared Issue with article?

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny - Nature Communications

|
By Theodore S Nowicki, Cole Peters, Egmidio Medina, Cristina Puig-Saus, Daniel G. Chen, Jonathan Rodriguez, Conner K. Kidd, Bartosz Chmielowski, Gary Schiller, Alexandra M. Klomhaus, David Baltimore, Donald Kohn, Mignonette H. Macabali, Moe Kawakami
| Nature Verified
Abstract Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo.
Open in Who Shared Issue with article?

1469 Hepatic artery pressure enabled drug delivery (PEDD) of nelitolimod combined with checkpoint inhibition (ICI) in uveal melanoma liver metastases (UM-LM) in ICI-naïve and -refractory patients (pts) | Journal for ImmunoTherapy of Cancer

|
By Richard D Carvajal, Diwakar Davar, Jose Lutzky, Bartosz Chmielowski
| The BMJ Verified
Abstract Background The hepatic tumor microenvironment (TME) is uniquely immunosuppressive in part because of myeloid-derived suppressor cells (MDSCs). This contributes to metastatic UM with liver metastases (LM) responding poorly to anti-PD1 based therapy.
Open in Who Shared Issue with article?
See all 19 licensed articles (24 Total)